{
    "meta": {
      "title": "Front Biomed - R&D & Services",
      "description": "Front Biomed focuses on anti-tumor biologics, novel chemical therapeutics, and stem cell translation, with full-stack services via our Cell Culture Research Center and Imaging Laboratory."
    },
    "banner": {
      "title": "R&D & Services"
    },
    "breadcrumb": {
      "home": "Home",
      "current": "R&D & Services"
    },
    "hero": {
      "strength_label": "Our Strength",
      "title": "Driven by Scientific Innovation",
      "subtitle": "We build efficient and reliable bioengineering solutions.",
      "paragraph": "Front Biomed’s wholly owned subsidiary has formed a core technical team of overseas-trained experts, including an academician, a Thousand Talents Program distinguished expert, and three tenured professors from U.S. universities. The advisory board spans academicians and leading scholars. Our pipeline centers on anti-tumor therapeutics, with 10+ programs already filed for international and Chinese patents."
    },
    "billboard": {
      "headline": "Pioneering Biomedical Research to Enable Breakthrough Therapies",
      "items": [
        {
          "title": "Anti-tumor Biologics",
          "text": "Led by two U.S.-based professors, our biologics team is advancing Par-4Ex (a modified PAR-4 polypeptide). The program has entered preclinical development with clear efficacy in animal models (prostate cancer) and is under invention patent review in China."
        },
        {
          "title": "Novel Chemical Therapeutics",
          "text": "In collaboration with a key laboratory at a C9/985 university, we develop MTH1 inhibitors. We have synthesized 50 novel compounds and validated dozens with strong MTH1 inhibition. Cell-based anti-cancer studies are progressing well and patent filings are underway."
        },
        {
          "title": "Stem Cell Translation",
          "text": "Together with a leading national stem cell evaluation committee team, we focus on exosome technologies and drive clinical translation for regenerative therapies—aiming to lead the field with forward-looking, high-impact solutions."
        }
      ]
    },
    "projects": {
      "title": "Ongoing Projects",
      "items": [
        "Targeted delivery of siMYC-AS1 and anti-PD-L1 via engineered MSC-derived exosomes for hepatocellular carcinoma",
        "Amniotic MSCs and exosomes for spinal cord injury and post-traumatic knee osteoarthritis repair",
        "Application of cytokines in cosmetic products",
        "Precision cell therapy for sub-healthy populations"
      ]
    },
    "labs": {
      "cell_culture": {
        "title": "Cell Culture Research Center",
        "bullets": [
          {
            "title": "Customized Serum Processing",
            "text": "Activated carbon, dialysis, heat inactivation, PEG treatment, low endotoxin, ultra-low IgG, gamma irradiation, and customizable bottle volumes."
          },
          {
            "title": "FBS Screening Standards",
            "text": "Multi-dimensional evaluation—passage stability, growth rate/state, and scale-up—to identify the best-fit serum for each cell line with reserved batch inventory."
          },
          {
            "title": "Serum-free Medium Development",
            "text": "Recombinant protein systems to mass-produce growth factors (EGF/FGF/IGF, etc.); co-develop highly adapted serum-free media tailored to specific cell lines."
          }
        ]
      },
      "imaging_lab": {
        "title": "Imaging Laboratory",
        "paragraph": "Front Tech partners with SCANCO Medical AG (Switzerland), the pioneer of Micro-CT, as the sole agent in Greater China, operating a Micro-CT Scanning Center that provides high-resolution preclinical imaging and analysis services. The center has run for 7+ years and serves ~100 universities and top hospitals."
      }
    }
  }
  